{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,24]],"date-time":"2025-08-24T23:04:22Z","timestamp":1756076662478,"version":"3.40.5"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,5,14]]},"DOI":"10.7759\/cureus.84110","type":"journal-article","created":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T16:32:51Z","timestamp":1747240371000},"source":"Crossref","is-referenced-by-count":1,"title":["When Two Worlds Collide: Navigating Diabetes in Cystic Fibrosis"],"prefix":"10.7759","author":[{"given":"Wisal","family":"Ahmad","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jansher","family":"Khan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmad J","family":"Hashmat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anusha","family":"Khan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aftab","family":"Ahmad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jalal","family":"Dildar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meenal","family":"Sikander","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sabeena","family":"Ahmad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shayan","family":"Zakir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Syed S","family":"Raza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saira K","family":"Awan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giustino","family":"Varrassi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.2337\/db22-0949","article-title":"Cystic fibrosis-related diabetes workshop: research priorities spanning disease pathophysiology, diagnosis, and outcomes","volume":"72","author":"Putman MS","year":"2023","unstructured":"Putman MS, Norris AW, Hull RL, et al.. Cystic fibrosis-related diabetes workshop: research priorities spanning disease pathophysiology, diagnosis, and outcomes. Diabetes. 2023, 72:677-89. 10.2337\/db22-0949","journal-title":"Diabetes"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccm.2022.06.013","article-title":"Endocrine complications of cystic fibrosis","volume":"43","author":"Kelly A","year":"2022","unstructured":"Kelly A, Marks BE, Stalvey MS. Endocrine complications of cystic fibrosis. Clin Chest Med. 2022, 43:773-89. 10.1016\/j.ccm.2022.06.013","journal-title":"Clin Chest Med"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0071-2024","article-title":"The ageing of people living with cystic fibrosis: what to expect now?","volume":"33","author":"Felipe Montiel A","year":"2024","unstructured":"Felipe Montiel A, Fern\u00e1ndez A\u00c1, Amigo MC, Traversi L, Clofent Alarc\u00f3n D, Reyes KL, Polverino E. The ageing of people living with cystic fibrosis: what to expect now?. Eur Respir Rev. 2024, 33:240071. 10.1183\/16000617.0071-2024","journal-title":"Eur Respir Rev"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.dsx.2023.102899","article-title":"Advances in cystic fibrosis-related diabetes: current status and future directions","volume":"17","author":"Lurquin F","year":"2023","unstructured":"Lurquin F, Buysschaert M, Preumont V. Advances in cystic fibrosis-related diabetes: current status and future directions. Diabetes Metab Syndr. 2023, 17:102899. 10.1016\/j.dsx.2023.102899","journal-title":"Diabetes Metab Syndr"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1111\/pedi.13453","article-title":"ISPAD Clinical Practice Consensus Guidelines 2022: management of cystic fibrosis-related diabetes in children and adolescents","volume":"23","author":"Ode KL","year":"2022","unstructured":"Ode KL, Ballman M, Battezzati A, et al.. ISPAD Clinical Practice Consensus Guidelines 2022: management of cystic fibrosis-related diabetes in children and adolescents. Pediatr Diabetes. 2022, 23:1212-28. 10.1111\/pedi.13453","journal-title":"Pediatr Diabetes"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabet.2023.101444","article-title":"Screening strategies for glucose tolerance abnormalities and diabetes in people with cystic fibrosis","volume":"49","author":"Weiss L","year":"2023","unstructured":"Weiss L, Reix P, Mosnier-Pudar H, et al.. Screening strategies for glucose tolerance abnormalities and diabetes in people with cystic fibrosis. Diabetes Metab. 2023, 49:101444. 10.1016\/j.diabet.2023.101444","journal-title":"Diabetes Metab"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1186\/s41073-019-0064-8","article-title":"SANRA-a scale for the quality assessment of narrative review articles","volume":"4","author":"Baethge C","year":"2019","unstructured":"Baethge C, Goldbeck-Wood S, Mertens S. SANRA-a scale for the quality assessment of narrative review articles. Res Integr Peer Rev. 2019, 4:5. 10.1186\/s41073-019-0064-8","journal-title":"Res Integr Peer Rev"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD004730.pub4","article-title":"Insulin and oral agents for managing cystic fibrosis-related diabetes","volume":"4","author":"Onady GM","year":"2016","unstructured":"Onady GM, Stolfi A. Insulin and oral agents for managing cystic fibrosis-related diabetes. Cochrane Database Syst Rev. 2016, 4:CD004730. 10.1002\/14651858.CD004730.pub4","journal-title":"Cochrane Database Syst Rev"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(17)30400-X","article-title":"Repaglinide versus insulin for newly diagnosed diabetes in patients with cystic fibrosis: a multicentre, open-label, randomised trial","volume":"6","author":"Ballmann M","year":"2018","unstructured":"Ballmann M, Hubert D, Assael BM, et al.. Repaglinide versus insulin for newly diagnosed diabetes in patients with cystic fibrosis: a multicentre, open-label, randomised trial. Lancet Diabetes Endocrinol. 2018, 6:114-21. 10.1016\/S2213-8587(17)30400-X","journal-title":"Lancet Diabetes Endocrinol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgz102","article-title":"Genetic modifiers of cystic fibrosis-related diabetes have extensive overlap with type 2 diabetes and related traits","volume":"105","author":"Aksit MA","year":"2020","unstructured":"Aksit MA, Pace RG, Vecchio-Pag\u00e1n B, et al.. Genetic modifiers of cystic fibrosis-related diabetes have extensive overlap with type 2 diabetes and related traits. J Clin Endocrinol Metab. 2020, 105:1401-15. 10.1210\/clinem\/dgz102","journal-title":"J Clin Endocrinol Metab"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.3928\/19382359-20160815-01","article-title":"Cystic fibrosis-related diabetes in children: an update","volume":"45","author":"Kim RJ","year":"2016","unstructured":"Kim RJ. Cystic fibrosis-related diabetes in children: an update. Pediatr Ann. 2016, 45:e321-6. 10.3928\/19382359-20160815-01","journal-title":"Pediatr Ann"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1080\/17512433.2018.1421065","article-title":"Pharmacological management of cystic fibrosis related diabetes","volume":"11","author":"Moheet A","year":"2018","unstructured":"Moheet A, Moran A. Pharmacological management of cystic fibrosis related diabetes. Expert Rev Clin Pharmacol. 2018, 11:185-91. 10.1080\/17512433.2018.1421065","journal-title":"Expert Rev Clin Pharmacol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1111\/apa.15155","article-title":"Cystic fibrosis in the year 2020: a disease with a new face","volume":"109","author":"De Boeck K","year":"2020","unstructured":"De Boeck K. Cystic fibrosis in the year 2020: a disease with a new face. Acta Paediatr. 2020, 109:893-9. 10.1111\/apa.15155","journal-title":"Acta Paediatr"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.3390\/genes11060589","article-title":"The changing epidemiology of cystic fibrosis: incidence, survival and impact of the CFTR gene discovery","volume":"11","author":"Scotet V","year":"2020","unstructured":"Scotet V, L'Hostis C, F\u00e9rec C. The changing epidemiology of cystic fibrosis: incidence, survival and impact of the CFTR gene discovery. Genes (Basel). 2020, 11:589. 10.3390\/genes11060589","journal-title":"Genes (Basel)"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1228153","article-title":"Effects of insulin therapy optimization with sensor augmented pumps on glycemic control and body composition in people with cystic fibrosis-related diabetes","volume":"14","author":"Grancini V","year":"2023","unstructured":"Grancini V, Alicandro G, Porcaro LL, et al.. Effects of insulin therapy optimization with sensor augmented pumps on glycemic control and body composition in people with cystic fibrosis-related diabetes. Front Endocrinol (Lausanne). 2023, 14:1228153. 10.3389\/fendo.2023.1228153","journal-title":"Front Endocrinol (Lausanne)"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1111\/dme.14121","article-title":"Loss of incretin effect contributes to postprandial hyperglycaemia in cystic fibrosis-related diabetes","volume":"36","author":"Frost F","year":"2019","unstructured":"Frost F, Jones GH, Dyce P, Jackson V, Nazareth D, Walshaw MJ. Loss of incretin effect contributes to postprandial hyperglycaemia in cystic fibrosis-related diabetes. Diabet Med. 2019, 36:1367-74. 10.1111\/dme.14121","journal-title":"Diabet Med"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2018.05.005","article-title":"Continuous glucose monitoring guided insulin therapy is associated with improved clinical outcomes in cystic fibrosis-related diabetes","volume":"17","author":"Frost F","year":"2018","unstructured":"Frost F, Dyce P, Nazareth D, Malone V, Walshaw MJ. Continuous glucose monitoring guided insulin therapy is associated with improved clinical outcomes in cystic fibrosis-related diabetes. J Cyst Fibros. 2018, 17:798-803. 10.1016\/j.jcf.2018.05.005","journal-title":"J Cyst Fibros"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.4158\/EP-2018-0461","article-title":"Markedly delayed insulin secretion and a high rate of undetected overt diabetes characterize glucose metabolism in adult patients with cystic fibrosis after lung transplantation","volume":"25","author":"Winhofer Y","year":"2019","unstructured":"Winhofer Y, Wolf P, Fellinger P, et al.. Markedly delayed insulin secretion and a high rate of undetected overt diabetes characterize glucose metabolism in adult patients with cystic fibrosis after lung transplantation. Endocr Pract. 2019, 25:254-62. 10.4158\/EP-2018-0461","journal-title":"Endocr Pract"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(19)30337-6","article-title":"The future of cystic fibrosis care: a global perspective","volume":"8","author":"Bell SC","year":"2020","unstructured":"Bell SC, Mall MA, Gutierrez H, et al.. The future of cystic fibrosis care: a global perspective. Lancet Respir Med. 2020, 8:65-124. 10.1016\/S2213-2600(19)30337-6","journal-title":"Lancet Respir Med"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.2337\/dc16-0020","article-title":"Does \u03b2-cell autoimmunity play a role in cystic fibrosis-related diabetes? Analysis based on the German\/Austrian Diabetes Patienten Verlaufsdokumentation Registry","volume":"39","author":"Konrad K","year":"2016","unstructured":"Konrad K, Kapellen T, Lilienthal E, et al.. Does \u03b2-cell autoimmunity play a role in cystic fibrosis-related diabetes? Analysis based on the German\/Austrian Diabetes Patienten Verlaufsdokumentation Registry. Diabetes Care. 2016, 39:1338-44. 10.2337\/dc16-0020","journal-title":"Diabetes Care"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/j.prrv.2023.12.005","article-title":"Cystic fibrosis liver disease in the new era of cystic fibrosis transmembrane conductance regulator (CFTR) modulators","volume":"50","author":"Eldredge JA","year":"2024","unstructured":"Eldredge JA, Oliver MR, Ooi CY. Cystic fibrosis liver disease in the new era of cystic fibrosis transmembrane conductance regulator (CFTR) modulators. Paediatr Respir Rev. 2024, 50:54-61. 10.1016\/j.prrv.2023.12.005","journal-title":"Paediatr Respir Rev"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1016\/j.prrv.2019.02.004","article-title":"Is it cystic fibrosis? The challenges of diagnosing cystic fibrosis","volume":"31","author":"Simmonds NJ","year":"2019","unstructured":"Simmonds NJ. Is it cystic fibrosis? The challenges of diagnosing cystic fibrosis. Paediatr Respir Rev. 2019, 31:6-8. 10.1016\/j.prrv.2019.02.004","journal-title":"Paediatr Respir Rev"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2015-3730","article-title":"HMGB1 is increased by CFTR loss of function, is lowered by insulin, and increases in vivo at onset of CFRD","volume":"101","author":"Montanini L","year":"2016","unstructured":"Montanini L, Cirillo F, Smerieri A, et al.. HMGB1 is increased by CFTR loss of function, is lowered by insulin, and increases in vivo at onset of CFRD. J Clin Endocrinol Metab. 2016, 101:1274-81. 10.1210\/jc.2015-3730","journal-title":"J Clin Endocrinol Metab"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1111\/pedi.12470","article-title":"Hypoglycemia is common in children with cystic fibrosis and seen predominantly in females","volume":"18","author":"Haliloglu B","year":"2017","unstructured":"Haliloglu B, Gokdemir Y, Atay Z, et al.. Hypoglycemia is common in children with cystic fibrosis and seen predominantly in females. Pediatr Diabetes. 2017, 18:607-13. 10.1111\/pedi.12470","journal-title":"Pediatr Diabetes"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.3390\/biom13030425","article-title":"Cystic fibrosis bone disease: the interplay between CFTR dysfunction and chronic inflammation","volume":"13","author":"Fonseca \u00d3","year":"2023","unstructured":"Fonseca \u00d3, Gomes MS, Amorim MA, Gomes AC. Cystic fibrosis bone disease: the interplay between CFTR dysfunction and chronic inflammation. Biomolecules. 2023, 13:425. 10.3390\/biom13030425","journal-title":"Biomolecules"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcjd.2017.10.024","article-title":"Cardiovascular protection in people with diabetes","volume":"42","author":"Stone JA","year":"2018","unstructured":"Stone JA, Houlden RL, Lin P, Udell JA, Verma S. Cardiovascular protection in people with diabetes. Can J Diabetes. 2018, 42:S162-9. 10.1016\/j.jcjd.2017.10.024","journal-title":"Can J Diabetes"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aav3488","article-title":"Mucus accumulation in the lungs precedes structural changes and infection in children with cystic fibrosis","volume":"11","author":"Esther CR Jr","year":"2019","unstructured":"Esther CR Jr, Muhlebach MS, Ehre C, et al.. Mucus accumulation in the lungs precedes structural changes and infection in children with cystic fibrosis. Sci Transl Med. 2019, 11:eaav3488. 10.1126\/scitranslmed.aav3488","journal-title":"Sci Transl Med"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.3390\/children10121879","article-title":"An update in cystic fibrosis-related diabetes in children and adolescents","volume":"10","author":"Anton-P\u0103duraru DT","year":"2023","unstructured":"Anton-P\u0103duraru DT, Murgu AM, Donos MA, et al.. An update in cystic fibrosis-related diabetes in children and adolescents. Children (Basel). 2023, 10:1879. 10.3390\/children10121879","journal-title":"Children (Basel)"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2013.02.008","article-title":"Update on cystic fibrosis-related diabetes","volume":"12","author":"Kelly A","year":"2013","unstructured":"Kelly A, Moran A. Update on cystic fibrosis-related diabetes. J Cyst Fibros. 2013, 12:318-31. 10.1016\/j.jcf.2013.02.008","journal-title":"J Cyst Fibros"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8227(11)70008-0","article-title":"New type 2 diabetes risk genes provide new insights in insulin secretion mechanisms","volume":"93","author":"Sch\u00e4fer SA","year":"2011","unstructured":"Sch\u00e4fer SA, Machicao F, Fritsche A, H\u00e4ring HU, Kantartzis K. New type 2 diabetes risk genes provide new insights in insulin secretion mechanisms. Diabetes Res Clin Pract. 2011, 93:S9-24. 10.1016\/S0168-8227(11)70008-0","journal-title":"Diabetes Res Clin Pract"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(16)30106-6","article-title":"Type 3c (pancreatogenic) diabetes mellitus secondary to chronic pancreatitis and pancreatic cancer","volume":"1","author":"Hart PA","year":"2016","unstructured":"Hart PA, Bellin MD, Andersen DK, et al.. Type 3c (pancreatogenic) diabetes mellitus secondary to chronic pancreatitis and pancreatic cancer. Lancet Gastroenterol Hepatol. 2016, 1:226-37. 10.1016\/S2468-1253(16)30106-6","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"ref32","article-title":"Bacterial culture isolates from infected diabetic foot tissue specimens and their sensitivity to antimicrobial agents","volume":"24","author":"Ayub R","year":"2016","unstructured":"Ayub R, Raza SS, Ullah S, Ahsan J, Hussain AK, Nadeem MD. Bacterial culture isolates from infected diabetic foot tissue specimens and their sensitivity to antimicrobial agents. J Med Sci. 2016, 24:273-7.","journal-title":"J Med Sci"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1007\/s00018-016-2391-y","article-title":"Role of CFTR in epithelial physiology","volume":"74","author":"Saint-Criq V","year":"2017","unstructured":"Saint-Criq V, Gray MA. Role of CFTR in epithelial physiology. Cell Mol Life Sci. 2017, 74:93-115. 10.1007\/s00018-016-2391-y","journal-title":"Cell Mol Life Sci"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics11030572","article-title":"Cystic fibrosis-related diabetes (CFRD): overview of associated genetic factors","volume":"11","author":"Iafusco F","year":"2021","unstructured":"Iafusco F, Maione G, Rosanio FM, Mozzillo E, Franzese A, Tinto N. Cystic fibrosis-related diabetes (CFRD): overview of associated genetic factors. Diagnostics (Basel). 2021, 11:572. 10.3390\/diagnostics11030572","journal-title":"Diagnostics (Basel)"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2024.111153","article-title":"Fatty acid abnormalities in cystic fibrosis-the missing link for a cure?","volume":"27","author":"Drzyma\u0142a-Czy\u017c S","year":"2024","unstructured":"Drzyma\u0142a-Czy\u017c S, Walkowiak J, Colombo C, et al.. Fatty acid abnormalities in cystic fibrosis-the missing link for a cure?. iScience. 2024, 27:111153. 10.1016\/j.isci.2024.111153","journal-title":"iScience"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.41697","article-title":"The effects of elexacaftor, tezacaftor, and ivacaftor (ETI) on blood glucose in patients with cystic fibrosis: a systematic review","volume":"15","author":"Salazar-Barragan M","year":"2023","unstructured":"Salazar-Barragan M, Taub DR. The effects of elexacaftor, tezacaftor, and ivacaftor (ETI) on blood glucose in patients with cystic fibrosis: a systematic review. Cureus. 2023, 15:e41697. 10.7759\/cureus.41697","journal-title":"Cureus"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.2337\/dc10-1768","article-title":"Clinical care guidelines for cystic fibrosis-related diabetes: a position statement of the American Diabetes Association and a clinical practice guideline of the Cystic Fibrosis Foundation, endorsed by the Pediatric Endocrine Society","volume":"33","author":"Moran A","year":"2010","unstructured":"Moran A, Brunzell C, Cohen RC, et al.. Clinical care guidelines for cystic fibrosis-related diabetes: a position statement of the American Diabetes Association and a clinical practice guideline of the Cystic Fibrosis Foundation, endorsed by the Pediatric Endocrine Society. Diabetes Care. 2010, 33:2697-708. 10.2337\/dc10-1768","journal-title":"Diabetes Care"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.45615","article-title":"The bidirectional link between diabetes and kidney disease: mechanisms and management","volume":"15","author":"Kumar M","year":"2023","unstructured":"Kumar M, Dev S, Khalid MU, et al.. The bidirectional link between diabetes and kidney disease: mechanisms and management. Cureus. 2023, 15:e45615. 10.7759\/cureus.45615","journal-title":"Cureus"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2015.12.011","article-title":"Advanced glycation end products are elevated in cystic fibrosis-related diabetes and correlate with worse lung function","volume":"15","author":"Hunt WR","year":"2016","unstructured":"Hunt WR, Helfman BR, McCarty NA, Hansen JM. Advanced glycation end products are elevated in cystic fibrosis-related diabetes and correlate with worse lung function. J Cyst Fibros. 2016, 15:681-8. 10.1016\/j.jcf.2015.12.011","journal-title":"J Cyst Fibros"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.2337\/dc17-1387","article-title":"Islet interleukin-1\u03b2 immunoreactivity is an early feature of cystic fibrosis that may contribute to \u03b2-cell failure","volume":"41","author":"Hull RL","year":"2018","unstructured":"Hull RL, Gibson RL, McNamara S, et al.. Islet interleukin-1\u03b2 immunoreactivity is an early feature of cystic fibrosis that may contribute to \u03b2-cell failure. Diabetes Care. 2018, 41:823-30. 10.2337\/dc17-1387","journal-title":"Diabetes Care"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2019.08.019","article-title":"Endocrine complications after solid-organ transplant in cystic fibrosis","volume":"18","author":"Sidhaye A","year":"2019","unstructured":"Sidhaye A, Goldswieg B, Kaminski B, Blackman SM, Kelly A. Endocrine complications after solid-organ transplant in cystic fibrosis. J Cyst Fibros. 2019, 18:S111-9. 10.1016\/j.jcf.2019.08.019","journal-title":"J Cyst Fibros"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1177\/2042018820966428","article-title":"Retinopathy and microalbuminuria are common microvascular complications in cystic fibrosis-related diabetes","volume":"11","author":"Kempegowda P","year":"2020","unstructured":"Kempegowda P, Sunsoa H, Chandan JS, et al.. Retinopathy and microalbuminuria are common microvascular complications in cystic fibrosis-related diabetes. Ther Adv Endocrinol Metab. 2020, 11:2042018820966428. 10.1177\/2042018820966428","journal-title":"Ther Adv Endocrinol Metab"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1007\/s11154-019-09516-w","article-title":"Diabetic lung disease: fact or fiction?","volume":"20","author":"Kolahian S","year":"2019","unstructured":"Kolahian S, Leiss V, N\u00fcrnberg B. Diabetic lung disease: fact or fiction?. Rev Endocr Metab Disord. 2019, 20:303-19. 10.1007\/s11154-019-09516-w","journal-title":"Rev Endocr Metab Disord"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1900\/RDS.2019.15.1","article-title":"Diabetes and lung disease: a neglected relationship","volume":"15","author":"Khateeb J","year":"2019","unstructured":"Khateeb J, Fuchs E, Khamaisi M. Diabetes and lung disease: a neglected relationship. Rev Diabet Stud. 2019, 15:1-15. 10.1900\/RDS.2019.15.1","journal-title":"Rev Diabet Stud"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/358860-when-two-worlds-collide-navigating-diabetes-in-cystic-fibrosis","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T16:32:52Z","timestamp":1747240372000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/358860-when-two-worlds-collide-navigating-diabetes-in-cystic-fibrosis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,14]]},"references-count":44,"URL":"https:\/\/doi.org\/10.7759\/cureus.84110","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5,14]]}}}